The drug, known as Breo Ellipta in the US, has already disappointed in one pivotal study. The Summit trial, published 12 months ago, showed the drug failed to cut the risk of death in COPD ...

Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

The precise mechanism through which fluticasone furoate affects COPD and asthma symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (eg ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD ... followed by Relvar/Breo Ellipta and Seretide ...